Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Mannheim – page 18

357 clinical trials in Mannheim, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Mannheim at a glance
357
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

357 trials in Mannheim

Open in trial search

Primary myelofibrosis

Not recruiting

Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Glaxosmithkline Research & Development Limited

Glioma

Not recruiting

Study on the Safety and Effectiveness of Vorasidenib and Temozolomide for Patients with IDH1 or IDH2 Mutant Glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Metastatic malignant melanoma+2

Not recruiting

Study of local treatment options for large metastases in patients with BRAF V600 mutated melanoma receiving encorafenib and binimetinib combination therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:SRH Wald-Klinikum Gera GmbH

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Generalised anxiety disorder

Not recruiting

Study on the Effects of MM120 (Lysergide) for Adults with Generalized Anxiety Disorder

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lysergide
  • Sponsor:Definium Therapeutics US Inc.

Metastatic malignant melanoma

Not recruiting

Study of BI-1607, Ipilimumab, and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI-1607
  • Sponsor:Bioinvent International AB

HIV infection

Not recruiting

Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

Primary mediastinal large B-cell lymphoma

Not recruiting

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitaet Muenster

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Heidelberg University

Philadelphia positive chronic myeloid leukaemia

Not recruiting

Study on Ponatinib for Achieving Treatment-Free Remission in Patients with Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ponatinib
  • Sponsor:Heidelberg University

Crohn's disease

Not recruiting

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 706321
  • Sponsor:Boehringer Ingelheim International GmbH

Acute graft versus host disease in intestine

Not recruiting

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Maat Pharma

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Mannheim

What the registry says about research in the country

01 Neurodegenerative Disorders

Clinical investigations focusing on Alzheimer's Disease and ALS, including trials of new therapeutic compounds for early-stage dementia and innovative treatments for motor neuron disease.

  • Early-stage Alzheimer's diagnostic tools
  • Novel drug therapies for neurodegenerative conditions
  • Disease progression monitoring

Research aims to improve brain amyloid clearance and evaluate new treatment approaches for neurological disorders.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for gastric cancer, melanoma, and breast cancer, with a focus on targeted therapies and immunological approaches.

  • HER2-expressing cancers
  • Metastatic melanoma treatments
  • Lymphoma therapies

Advanced treatments combining immunotherapy with established protocols to improve patient outcomes.

03 Inflammatory Conditions

Studies addressing inflammatory disorders, particularly focusing on Crohn's Disease, ulcerative colitis, and uveitis, testing novel therapeutic combinations.

  • Gastrointestinal disorders
  • Autoimmune conditions
  • Combination therapy approaches

Innovative treatment strategies aimed at improving disease management and patient quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.